P293. eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis
N. Pedersen1,2, J. Burisch3, L. Martinsen4, M. Bennedsen5, P. Thielsen6, S. Bell7, Z. Vegh3, A. Haaber8, D. Duricova9, T. Jess10, E. Langholz11, P. Munkholm3, 1Herlev University Hospital, Department of Gastroenterology, Copenhagen, Denmark, 2University, Gastroenterology, Copenhagen, Denmark, 3University of Copenhagen, Gastroenterology, Herlev, Denmark, 4Nykøbing Falster Hospital, Gastroenterology, Nykøbing Falster, Denmark, 5Frederikssund Hospital, Gastroenterology, Frederikssund, Denmark, 6Herlev University Hospital, Gastroenterology, Herlev, Denmark, 7University of Melbourne, Gastroenterology, Melbourne, Australia, 8Gentofte Hospital, Gastroenterology, Gentofte, Denmark, 9Charls University Hospital, IBD research centre ISCARE a.s., Herlev, Denmark, 10State Serum Institute, Epidemiology, Copenhagen, Denmark, 11Gentofte, Gastroenterology, Gentofte, Denmark
Treatment with MMX mesalamine to induce remission in patients with ulcerative colitis (UC) with activity has been shown to be efficient as first line therapy. The objective of this study was to individualise treatment with MMX mesalamine treatment and optimise the short-term disease course via a self-managed web-based solution in relapsed Ulcerative colitis.
Observational, open-labelled three months treatment with MMX mesalamine of 95 relapsed UC patients via a web-application. Patients had to fill out weekly during three months the simple clinical colitis activity index scale (SCCAI) and faecal calprotectin (FC) on web application: www.meza.constant-care.dk. We investigated the short-term MMX mesalamine monoterapy efficacy and the feasibility of web-guided therapy in relapsed UC patients.
A total of 95 patients with mild–moderate UC: 59 (62%) females, median age 45 years (19–77) were included in the study and allocated to 4.8 g MMX mesalamine. 82 (86%) patients were adherent to web-therapy completing three month self-managed web-guided MMX mesalamine therapy: 72/82 (88%) complete responders and 10/82 (12%) non-responders.
At week 12, all patients had a significant reduction (mean week 0 vs. mean week 12) of SCCAI (4.6 vs. 1.6), FC (437 vs. 195) and TIBS (6.7 vs. 2.4) respectively, p < 0.001.
MMX mesalamine is effective in IBD patients in remission or mild-to moderate activity, predominantly improving SCCAI and FC values in more than half patients and could be used in cases of non-adherence with and insufficient response on combined oral and topic 5-ASA therapy. Web-guided therapy in colitis individualise the dosis and improve adherence to therapy.